Growth hormone secretagogues: research overview of GHRH and GHRP peptide classes

What is a growth hormone secretagogue?

“Growth hormone secretagogue” (GHS) is an umbrella term for any compound that stimulates the body's own secretion of growth hormone — working through existing regulatory pathways rather than supplying growth hormone directly. That single definition covers two mechanistically distinct peptide classes that are frequently discussed together but act on entirely different receptors.

Treating “GH secretagogue” as one category obscures more than it explains. Identifying which class a compound belongs to — and why that matters mechanistically — is the more useful starting point for any research protocol involving GH-pathway peptides.

The two mechanistic classes

Class 1: GHRH analogs. These peptides interact directly with GHRH receptors in the anterior pituitary, stimulating the same synthesis and secretion pathway endogenous GHRH uses. Studied compounds include tesamorelin, CJC-1295, and sermorelin. Because they work through the natural pathway, their effect remains subject to somatostatin's inhibitory tone — raising the baseline drive for GH production while staying inside the body's existing feedback system. Tesamorelin is the most clinically established compound in the class, having completed Phase III trials and received FDA approval for a specific indication.

Class 2: GHRP / ghrelin receptor agonists. This class acts on GHSR-1a, the ghrelin receptor, rather than the GHRH receptor. Studied compounds include ipamorelin, hexarelin, GHRP-2, and GHRP-6. Mechanistically they amplify GH pulse amplitude and reduce somatostatin's inhibitory tone, working synergistically with GHRH signalling rather than instead of it. Selectivity varies within the class: ipamorelin is frequently noted for a more selective profile with limited observed interaction with prolactin and cortisol pathways, a meaningful distinction from earlier-generation compounds such as GHRP-6.

Why these classes are often studied together

Because the two classes act on distinct receptors, research has examined their combination specifically for interactive effects on GH pulse amplitude and frequency — the mechanisms are complementary rather than redundant. Published clinical research on CJC-1295 (Teichman et al., Journal of Clinical Endocrinology & Metabolism, 2006) demonstrated prolonged stimulation of both GH and IGF-1 secretion in healthy adults, establishing pharmacokinetic groundwork later combination research has built on.

What the research literature covers

• Receptor characterisation and structural biology: substantial work on the GHRH receptor itself — a Class B1 GPCR — including its two-step activation model and its relevance as a potential oncology drug target given overexpression in several cancer types.
• Comparative pituitary research: cross-species pituitary culture studies examining how GHRH, ghrelin, and related peptides differentially regulate GH secretion across reptiles, birds, and mammals.
• Selectivity and side-effect profiling: comparing which compounds stimulate GH release with minimal off-target effects on cortisol, prolactin, and appetite-related pathways, since ghrelin receptor activation is also tied to feeding behaviour in preclinical models.
• Clinical-grade evidence: tesamorelin is the one compound in the space with Phase III trial data and FDA approval — a different evidence tier from the rest of the class, which remains largely preclinical or early-phase.

Purity and research-grade considerations

Because GH secretagogue research often involves comparing or combining compounds from both classes, batch-to-batch consistency is particularly important for interpreting combination studies. HPLC-verified purity and a batch-specific Certificate of Analysis remain the baseline standard for any compound in this class.

Summary

Growth hormone secretagogues split into two mechanistically distinct classes: GHRH analogs (tesamorelin, CJC-1295, sermorelin), which work through the pituitary's natural GHRH receptor pathway, and GHRP / ghrelin receptor agonists (ipamorelin, hexarelin, GHRP-2, GHRP-6), which act on a separate receptor to amplify GH pulse characteristics. Selectivity varies meaningfully within the second class, and only tesamorelin currently carries clinical-trial-grade evidence and regulatory approval — the rest of the category remains an active but earlier-stage research area.